Evolution Capital Management’s eFFECTOR Therapeutics EFTR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
$226K Hold
21,115
– – 0.78% 25
2022
Q3
$302K Hold
21,115
– – 0.44% 20
2022
Q2
$750K Buy
+21,115
New +$1.28M 1.12% 11

Other funds holding EFTR

Evolution Capital Management's EFTR Position: Q4 2022 in Review

Evolution Capital Management held its eFFECTOR Therapeutics (EFTR) position steady in Q4 2022 at 21,115 shares worth $226K. The position accounts for 0.78% of the portfolio, ranked #25.

Evolution Capital Management first reported a position in EFTR in Q2 2022 and has held it in 3 quarters since. The position peaked at $750K in Q2 2022. 30 funds tracked by Wall St. Rank hold EFTR as of Q4 2022.

  • Evolution Capital Management held 21,115 shares of eFFECTOR Therapeutics worth $226K as of Q4 2022.
  • Evolution Capital Management left its eFFECTOR Therapeutics share count unchanged in Q4 2022.
  • eFFECTOR Therapeutics made up 0.78% of Evolution Capital Management's portfolio in Q4 2022, its #25 holding.
  • Evolution Capital Management first reported a position in eFFECTOR Therapeutics in Q2 2022 and has held it in 3 quarters since.
  • Evolution Capital Management's eFFECTOR Therapeutics position peaked at $750K in Q2 2022.
  • 30 funds tracked by Wall St. Rank held eFFECTOR Therapeutics as of Q4 2022.

Based on Evolution Capital Management's 13F filing for Q4 2022, filed 13 Feb 2023.